NYSEJNJ

Reporting its Q1 2024 results, Big Pharma’s earnings bellwether, Johnson & Johnson (NYSE:JNJ), revised its full-year outlook below consensus on Tuesday after sales from its MedTech division fell short of Street forecasts. JNJ shares…

Hailshadow Johnson & Johnson (NYSE:JNJ) announced Tuesday that its FDA-approved multiple myeloma therapy Darzalex Faspro in a combination regimen cut the risk of disease progression or death by 58% compared to standard of care in a…